Abstract: An anti-BCMA antibody or an antigen-binding fragment thereof, and an application thereof in the treatment or prevention of tumor.

Abstract: An air conditioner defrosting method. In the air conditioner’s heating process, after the end of every defrosting procedure, the temperature of the outdoor heat exchanger coil and the time used over the course of the defrosting procedure can be measured and recorded. The defrosting situation of the air conditioner is reflected, and an initial determination of whether there is frost accumulation is made. After the initial determination, the air conditioner continues carrying out the heating procedure, and when specific conditions are met, it carries out a third defrosting procedure. When second determination results indicate that there is frost accumulation, the frost accumulation problem is deemed to be quite severe with a risk of icing up, and it is necessary to conduct forced intervention and carry out forced defrosting steps.

Abstract: Disclosed is an impurity removal and modification method for pyrolysis carbon black of waste tires, the method comprising: dispersing pyrolysis carbon black of waste tires in an alkali solution of potassium ferrate; adding hypohalite; leaving to stand for layering; and performing centrifugation and washing on a lower-layer slurry to obtain a stably dispersed pyrolysis carbon black/water suspension. This modification method can be operated simply and easily; and by means of the method, ash in pyrolysis carbon black of waste tires can be effectively removed, and the pyrolysis carbon black is then stably dispersed in water. In addition, the modification method is low in production cost, and is green and environmentally friendly, and a waste liquid thereof can be recycled.

Abstract: Provided are non-naturally occurring cystine knot peptides (CKPs) that bind to VEGF-A. Additionally, provided are methods of using non-naturally occurring CKPs that bind to VEGF-A, including diagnostic and therapeutic compositions and methods. Non-naturally CKPs that bind low density lipoprotein receptor-related protein 6 (LRP6) are also provided.

Abstract: A preparation method includes 1) dispersing cellulose nanocrystal in water and adjusting pH to 7; 2) adding carboxylate to the aqueous dispersion of the step 1), and stirring until uniform; and 3) adding a monomer and a ceric ammonium nitrate initiator to the system of the step 2), reacting for 0.5-3 h to obtain a precipitate, and subjecting the precipitate to suction filtration, washing, and drying to obtain the cellulose nanocrystal powder. By adding a small amount of carboxylate into a cellulose nanocrystal graft polymer modification system initiated by ceric ammonium nitrate, hydrolysis of cerium ions can be inhibited through complexation of the carboxylate to the cerium ions which play an initiating role in ceric ammonium nitrate, so that ceric ammonium nitrate can initiate the polymerization reaction under acid-free conditions, thereby achieving polymerization of polyvinyl acetate monomer on the surface of cellulose nanocrystals.

Abstract: Implementations include processing a set of documents using an auto-encoder to provide a first sub-set of documents, the first sub-set of documents including electronic documents with a relatively high likelihood of providing true positives in an auditing process, processing a sub-set of documents using a set of auto-generated rules to provide a second sub-set of documents, the second sub-set of documents including electronic documents with a relatively high likelihood of providing false positives in an auditing process, and defining a master set of documents for the auditing process based on the sub-set of documents, the first sub-set of documents, and the second sub-set of documents, the master set of documents including at least a portion of the sub-set of documents, and at least a portion of the first sub-set of documents, and being absent the second sub-set of documents.

Abstract: Provided are non-naturally occurring cystine knot peptides (CKPs) that bind to VEGF-A. Additionally, provided are methods of using non-naturally occurring CKPs that bind to VEGF-A, including diagnostic and therapeutic compositions and methods. Non-naturally CKPs that bind low density lipoprotein receptor-related protein 6 (LRP6) are also provided.

Abstract: Provided are non-naturally occurring cystine knot peptides (CKPs) that bind to VEGF-A. Additionally, provided are methods of using non-naturally occurring CKPs that bind to VEGF-A, including diagnostic and therapeutic compositions and methods. Non-naturally CKPs that bind low density lipoprotein receptor-related protein 6 (LRP6) are also provided.

Abstract: Provided are non-naturally occurring cystine knot peptides (CKPs) that bind to VEGF-A. Additionally, provided are methods of using non-naturally occurring CKPs that bind to VEGF-A, including diagnostic and therapeutic compositions and methods. Non-naturally CKPs that bind low density lipoprotein receptor-related protein 6 (LRP6) are also provided.

Abstract: Provided are non-naturally occurring cystine knot peptides (CKPs) that bind to VEGF-A. Additionally, provided are methods of using non-naturally occurring CKPs that bind to VEGF-A, Including diagnostic and therapeutic compositions and methods. Non-naturally CKPs that bind low density lipoprotein receptor-related protein 6 (LRP6) are also provided.

Abstract: Provided are non-naturally occurring cystine knot peptides (CKPs) that bind to VEGF-A. Additionally, provided are methods of using non-naturally occurring CKPs that bind to VEGF-A, including diagnostic and therapeutic compositions and methods. Non-naturally CKPs that bind low density lipoprotein receptor-related protein 6 (LRP6) are also provided.

Abstract: Provided are non-naturally occurring cystine knot peptides (CKPs) that bind to VEGF-A. Additionally, provided are methods of using non-naturally occurring CKPs that bind to VEGF-A, including diagnostic and therapeutic compositions and methods. Non-naturally CKPs that bind low density lipoprotein receptor-related protein 6 (LRP6) are also provided.

Abstract: Implementations include processing a set of documents using an auto-encoder to provide a first sub-set of documents, the first sub-set of documents including electronic documents with a relatively high likelihood of providing true positives in an auditing process, processing a sub-set of documents using a set of auto-generated rules to provide a second sub-set of documents, the second sub-set of documents including electronic documents with a relatively high likelihood of providing false positives in an auditing process, and defining a master set of documents for the auditing process based on the sub-set of documents, the first sub-set of documents, and the second sub-set of documents, the master set of documents including at least a portion of the sub-set of documents, and at least a portion of the first sub-set of documents, and being absent the second sub-set of documents.

Abstract: Provided are non-naturally occurring cystine knot peptides (CKPs) that bind to VEGF-A. Additionally, provided are methods of using non-naturally occurring CKPs that bind to VEGF-A, including diagnostic and therapeutic compositions and methods. Non-naturally CKPs that bind low density lipoprotein receptor-related protein 6 (LRP6) are also provided.

Abstract: Provided are non-naturally occurring cystine knot peptides (CKPs) that bind to VEGF-A. Additionally, provided are methods of using non-naturally occurring CKPs that bind to VEGF-A, including diagnostic and therapeutic compositions and methods. Non-naturally CKPs that bind low density lipoprotein receptor-related protein 6 (LRP6) are also provided.

Abstract: Provided are non-naturally occurring cystine knot peptides (CKPs) that bind to VEGF-A. Additionally, provided are methods of using non-naturally occurring CKPs that bind to VEGF-A, including diagnostic and therapeutic compositions and methods. Non-naturally CKPs that bind low density lipoprotein receptor-related protein 6 (LRP6) are also provided.

Abstract: Provided are non-naturally occurring cystine knot peptides (CKPs) that bind to VEGF-A. Additionally, provided are methods of using non-naturally occurring CKPs that bind to VEGF-A, including diagnostic and therapeutic compositions and methods. Non-naturally CKPs that bind low density lipoprotein receptor-related protein 6 (LRP6) are also provided.

Abstract: DNA amplification methods using novel primers obtained from the novel genes hyvI and hyvII from the Candidatus Liberibacter asiaticus genome are useful for detecting Ca. L. species in plants and insect hosts.

Abstract: DNA amplification methods using novel primers obtained from the novel genes hyvI and hyvII from the Candidatus Liberibacter asiaticus genome are useful for detecting Ca. L. species in plants and insect hosts.

Abstract: DNA amplification methods using primers obtained from the genes hyvI and hyvII from the Candidatus Liberibacter asiaticus genome are useful for detecting Ca. L. species in plants and insect hosts.